#United States #South San Francisco #uveal melanoma #darovasertib #crizotinib

IDEAYA Biosciences and Servier Launch a Vital Clinical Trial for Uveal Melanoma

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2026 – In a significant breakthrough for treating uveal melanoma, IDEAYA Biosciences, Inc. and Servier have announced the first patient is now enrolled and initiated treatment in the global Phase 3 clinical trial known as OptimUM-11. This trial is particularly vital as it combines darovasertib, an innovative oral protein kinase C (PKC) inhibitor, with crizotinib, an oral cMET inhibitor, to provide an adjuvant therapy option for patients at a heightened risk of metastasis following local treatment.

Uveal melanoma, a rare and aggressive form of cancer originating from melanocytes in the eye, presents substantial challenges to both patients and healthcare providers. Current treatment protocols primarily focus on local therapies such as plaque brachytherapy and enucleation. However, there's no approved adjuvant treatment specifically for patients with primary uveal melanoma who have completed local therapy, leading to a critical gap in patient care. With the recent dosing of the first patient, the OptimUM-11 trial aims to fill this unmet need by evaluating the effectiveness of the darovasertib and crizotinib combination.

A Collaborative Approach to Addressing Treatment Gaps

Dr. Darrin M. Beaupre, Chief Medical Officer at IDEAYA, emphasized the importance of this milestone in developing a treatment protocol that could significantly alter the trajectory of care for patients. "Patients diagnosed with primary uveal melanoma face a considerable risk of developing metastatic disease following their initial treatment. By introducing a systemic therapy in the adjuvant setting, we hope to delay or completely prevent disease progression and improve patient outcomes," he stated. The consensus among medical professionals is clear—there's an urgent need for new options, especially as nearly half of primary uveal melanoma patients ultimately experience a metastatic recurrence.

Servier's Executive Vice President, Arnaud Lallouette, echoed this sentiment, highlighting how "The OptimUM-11 trial represents a joint effort to pioneer a new approach in treating high-risk uveal melanoma patients. Our collaboration with IDEAYA is pivotal to advancing research aimed at establishing an effective treatment that can change the lives of these patients worldwide."

The Trial's Framework and Goals

The OptimUM-11 trial is structured to include approximately 450 patients who have completed initial local therapy but are at increased risk for metastasis. Participants will be randomly assigned to either receive darovasertib in conjunction with crizotinib or be placed under observation for 12 months. The primary goal is to measure relapse-free survival, a significant indicator of the regimen's effectiveness.

IDEAYA maintains regulatory and commercial rights for darovasertib within the United States, while Servier oversees external markets. Both companies are committed to sharing the costs associated with clinical development, thus highlighting their dedication to improving treatment access and outcomes.

Understanding Darovasertib's Role

Designed as a first-in-class oral small-molecule inhibitor, darovasertib aims to target PKC isoforms linked to genetic mutations that drive uveal melanoma's aggressive nature. This compound is already under evaluation in various clinical studies, addressing different stages of uveal melanoma, including both neoadjuvant and adjuvant therapies. In addition to its clinical applications, darovasertib has been granted multiple designations by the U.S. Food and Drug Administration (FDA) that underscore its potential usefulness in combating this rare form of cancer.

A Broader Context

Globally, the incidence of primary uveal melanoma fluctuates, with estimates indicating about 10,000 to 12,000 new cases diagnosed each year. In the United States, over 3,000 new cases arise annually, showcasing the necessity for dedicated research and treatment strategies. With the initiation of the OptimUM-11 trial, IDEAYA and Servier aim to enhance the options available to families facing the harsh realities of uveal melanoma, particularly as metastatic consequences can seriously impact long-term survival.

This collaborative effort showcases the potential for innovation in cancer therapy and reaffirms the commitment of IDEAYA and Servier to advance the treatment landscape for uveal melanoma.

As the trial progresses, both companies will keep a close eye on the outcomes, ensuring that their collective mission to enhance the quality of life for uveal melanoma patients remains a top priority. Overall, the OptimUM-11 trial stands as a beacon of hope for many, paving the way for future breakthroughs in oncology and patient care.